Company AlloVir, Inc.

Equities

ALVR

US0198181036

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Real-time Estimate Cboe BZX Other stock markets 02:42:52 2024-05-21 pm EDT			5-day change	1st Jan Change
0.787 ^USD	+2.35%		+1.35%	+15.11%

May. 13	AlloVir, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 20	North American Morning Briefing : Markets on Hold -2-	DJ

AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The companyâs proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. Its technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. Its lead product candidate, posoleucel, is a multi-VST therapy that targets six viruses: adenovirus (BKV), cytomegalovirus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV). Its proprietary VST manufacturing platform enables the rapid, robust and reproducible generation of single-virus and multi-virus specific cell therapeutic candidates for clinical use.

Number of employees: 15

Managers	Title	Age	Since
Juan Vera FOU	Founder	44	13-07-31
Ann M. Leen FOU	Founder	47	13-07-31
Diana Brainard CEO	Chief Executive Officer	53	19-03-31
David Hallal CHM	Chairman	57	18-08-31
Vikas Sinha PSD	President	60	18-08-31
Brett Hagen AUD	Comptroller/Controller/Auditor	51	18-12-31
Edward Miller LAW	General Counsel	59	18-12-31

Members of the board	Title	Age	Since
Vikas Sinha PSD	President	60	18-08-31
Morana Jovan-Embiricos BRD	Director/Board Member	57	19-04-30
David Hallal CHM	Chairman	57	18-08-31
Jeffrey Bornstein BRD	Director/Board Member	57	20-06-30
Shawn Tomasello BRD	Director/Board Member	65	22-03-28
Derek Adams BRD	Director/Board Member	50	23-02-28
Diana Brainard CEO	Chief Executive Officer	53	19-03-31
Malcolm Brenner FOU	Founder	72	13-07-31
Juan Vera FOU	Founder	44	13-07-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	115,003,325	58,363,215 ( 50.75 %)	0	50.75 %

Name	Equities	%	Valuation
ElevateBio LLC 14.51 %	16,674,766	14.51 %	13 M $
GILEAD SCIENCES, INC. 14.48 %	16,635,286	14.48 %	13 M $
EcoR1 Capital, LLC 9.829 %	11,294,585	9.829 %	9 M $
EcoR1 Capital, LLC 9.273 %	10,655,366	9.273 %	9 M $
Morana Jovan-Embiricos 8.640 %	9,928,288	8.640 %	8 M $
Artal Group SA 5.741 %	6,597,167	5.741 %	5 M $
John Wilson 4.661 %	5,355,877	4.661 %	4 M $
Octagon Capital Advisors LP 3.655 %	4,200,000	3.655 %	3 M $
BlackRock Advisors LLC 2.827 %	3,248,053	2.827 %	3 M $
Millennium Management LLC 2.561 %	2,942,608	2.561 %	2 M $

AlloVir, Inc.

1100 Winter Street

02451, Waltham

http://www.allovir.com

Sell

Buy

Mean consensus

UNDERPERFORM

Number of Analysts

Last Close Price

0.7689 USD

Average target price

0.975 USD

Spread / Average Target

+26.80%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
ALLOVIR, INC.	+14.31%	87.22M
VERTEX PHARMACEUTICALS INCORPORATED	+9.71%	115B
REGENERON PHARMACEUTICALS, INC.	+13.26%	107B
BIONTECH SE	-13.33%	22.31B
ARGENX SE	-3.38%	21.6B
BEIGENE, LTD.	-5.71%	18.23B
WUXI APPTEC CO., LTD.	-38.57%	17.62B
NEUROCRINE BIOSCIENCES, INC.	+7.79%	14.26B
SAREPTA THERAPEUTICS, INC.	+34.37%	12.37B
LEGEND BIOTECH CORPORATION	-26.73%	8.28B

Bio Therapeutic Drugs